“It is estimated that by the end of 2020, there will be millions of doses of vaccine produced and licensed, creating a premise to scale up hundreds of millions of doses by 2021,” – said pharmaceutical firm Pfizer.
CNN reported that BioNTech – a German company cooperated with Pfizer – a giant pharmaceutical company from the United States to conduct a test against the anti-Covid-19 vaccine in humans. The two companies said if successful, they could deliver millions of doses of vaccine by the end of 2020.
RelatedPosts
Pfizer announced that it will conduct a new vaccine trial in the US this week, and said there would be an emergency vaccine release right in the fall of this year. And BioNTech some candidates have tried this vaccine, called BNT162.
“12 candidates have been vaccinated with BNT162 in Germany since the start of the study on April 23,” – the company said.
There is currently no information about the results of the test. BioNTech said about 200 candidates between the ages of 18 and 55 will be tested at different doses to find the most effective numbers for future studies.
“Besides, the safety properties and genetic immunity of the vaccine will also be explored,” – quoted information provided from BioNTech.
Currently, both companies are applying for BNT162 license in the US, which is expected to be completed in the near future. In Germany, the vaccine test was approved on April 22.
“The two companies have cooperated to test the Covid-19 vaccine on humans, starting in Europe and the US,” – Pfizer announced. “It is estimated that by the end of 2020, there will be millions of doses of vaccine produced and licensed, creating the premise to scale up hundreds of millions of doses by 2021.”
Pfizer is also currently not the only pharmaceutical corporation developing Covid-19 vaccine. Last week, experts at Oxford University also conducted a vaccine on humans, and depending on the results that can produce the final product in September. Health officials said, half of the chapters The Covid-19 vaccine research program is currently in beta, with 80 preliminary studies on a global scale.
